← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #356 OF 1,000 MOST-CITED

Eligibility not required--warning labels

FDA cited this observation 58 times across 51 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Human Tissue for Transplantation58
BY FISCAL YEAR
FY20259
FY202412
FY20237
FY20227
FY20216
FY20204
FY20198
FY20184
FY20171

How FDA worded it — real examples

HCT/Ps for which the donor eligibility determination was not required were not prominently labeled with the appropriate warning statements.

University of Chicago Hospitals · Chicago, Illinois · Human Tissue for Transplantation · 2025-07-17

HCT/Ps for which the donor eligibility determination was not required were not prominently labeled with the appropriate warning statements.

Arizona Reproductive Medicine Specialists · Phoenix, Arizona · Human Tissue for Transplantation · 2025-06-30

HCT/Ps for which the applicable donor eligibility requirements were not met were not prominently labeled with the appropriate warning statements.

Ohio Fertility Providers LLC · Cincinnati, Ohio · Human Tissue for Transplantation · 2025-05-15

HCT/Ps for which the donor eligibility determination was not required and applicable donor eligibility requirements were not met were not prominently labeled with the appropriate warning statements.

Fort Worth Fertility P.A. · Fort Worth, Texas · Human Tissue for Transplantation · 2025-04-24

HCT/Ps for which the donor eligibility determination was not required and applicable donor eligibility requirements were not met were not prominently labeled with the appropriate warning statements.

Kofinas Fertility Group · New York, New York · Human Tissue for Transplantation · 2025-04-09

HCT/Ps for which the donor eligibility determination was not required and applicable donor eligibility requirements were not met were not prominently labeled with the appropriate warning statements.

New York Reproductive Wellness Medicine, P.C. · Syosset, New York · Human Tissue for Transplantation · 2025-03-28

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →